首页> 外文期刊>Hepato-gastroenterology. >Sixteen Consecutive Adult Intestinal Transplantation: A Single-Center Clinical Experience in China
【24h】

Sixteen Consecutive Adult Intestinal Transplantation: A Single-Center Clinical Experience in China

机译:连续十六次成人肠道移植:在中国的单中心临床经验

获取原文
获取原文并翻译 | 示例
           

摘要

(Background/Aims: The aim of the paper is to describe a single-center experience of adult small intestine transplantation (ITx). Methodology: 15 ITx and 1 combined liver and ITx(L/ITx) had performed. The immunosuppressive regimen was based on induction therapy with two different protocols: In Period I (pre-2006, n=10), daclizumab or without for induction, high dose tacrolimus, mycophenolate mofetil and steroids as maintenance therapy; In Period II (post-2006, n=6), alemtuzumab for induction and low dose tacrolimus as maintenance anti-rejection treatment unless required for, steroids were not routinely used. Results: In Period I, 9 ITx and 1 L/ITx were performed. One patient survived more than 1-year with normal bowel function and 1 recipient survived more than 4 years with partial PN. Seven patients died within one year. The main cause of Surgical death was sepsis. In period II, 4 patients have a normal patients are on partial PN. The main cause of death was rejection. Conclusion: The survival of intestinal transplantation has greatly improved over time as management strategies evolved. However, certain unresolved issues still requires future investigation include new strategies to prevent late complications and the causes.
机译:(背景/目的:本文的目的是描述成人小肠移植(ITx)的单中心经验。方法:进行了15例ITx和1例联合肝脏和ITx的联合治疗(L / ITx)。有两种不同方案的诱导疗法:在I期(2006年之前,n = 10),达克珠单抗或不进行诱导,高剂量他克莫司,霉酚酸酯和类固醇作为维持疗法;在II期(2006年之后,n = 6) ),除非有必要,否则使用alemtuzumab进行诱导和低剂量他克莫司作为维持抗排斥治疗,除非常规,否则不常规使用类固醇。肠功能正常,部分PN患者生存超过4年,一年内死亡7例,手术死亡的主要原因是败血症;在II期,部分PN患者4例正常。死亡就是拒绝。结论:随着管理策略的发展,肠道移植的存活率随着时间的推移已大大提高。但是,某些未解决的问题仍然需要将来进行调查,包括防止晚期并发症和原因的新策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号